Equity Overview
Price & Market Data
Price: $2.37
Daily Change: -$0.08 / 3.38%
Daily Range: $2.20 - $2.54
Market Cap: $267,581,920
Daily Volume: 371,059
Performance Metrics
1 Week: 16.84%
1 Month: 49.67%
3 Months: 87.70%
6 Months: 237.6%
1 Year: 120.2%
YTD: 228.9%
Company Details
Employees: 9
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.